Dr. Sorayya received his Bachelor of Science degree with honors in Biology from Stanford University in 2017, followed by a Doctor of Medicine from the Virginia Tech Carilion School of Medicine in 2022. Currently, Dr. Sorayya is honing his expertise in patient care through a residency in family medicine at John Muir Health. Dr. Sorayya is a co-inventor of 3 patents on Engimata’s adjuvant technology and as a high school student intern at HTD Biosystems (2011-2014), he received over 20 scientific awards including the notable project of the year award at the 2012 California State Science Fair, and the 1st place award at the 2014 Intel International Science Fair. During his freshman year at Stanford, and as a cofounder and president of Engimata Inc. he competed in the Business Association of Stanford Engineering Students (BASES) product challenge and SENSA (Social entrepreneurship challenge), where Engimata was a finalist among 50 companies and placed 6th in BASES and was a runner up in SENSA. While a student at Stanford, he also conducted research in biology at NASA Ames in the lab of Dr. Lynn Rothschild as a member of the Stanford iGEM team, and at the School of Medicine Department of Cardiology at the Joe Wu lab, where he worked with stem cells and gene editing technology. In this role he also conducted part of his studies at the Palo Alto VA hospital. After graduation from Stanford, he served as a life science professional at the Laura Attardi lab in Stanford University, where he worked on developmental biology. He continued his research endeavors at the Virginia Tech Medical School by conducting cancer research at the Lamouille Lab. Dr. Sorayya's scholarly contributions include authoring three publications and holding three issued US patents. Additionally, Dr. Sorayya is fluent in five languages, which enhances his ability to connect with diverse populations and colleagues globally, further enriching his professional and personal interactions in the field of medicine.
Engimata is an early stage biopharma company located in the San Francisco Bay Area. Engimata has a platform nano lipid particle technology that can be used in vaccine development.
